Teijin Pharma and Merz Therapeutics have secured MHLW approval in Japan for XEOMIN® (incobotulinumtoxinA) to treat cervical dystonia and blepharospasm, adding two new indications to the product's Japanese portfolio. For overseas aesthetic distributors and clinic buyers, this signals a validated regulatory pathway for a purified neurotoxin in a high-barrier market, potentially opening supply-chain opportunities for devices, consumables, and injectables linked to the expanding botulinum toxin segment in Japan.
Approval details and market context
Japan's Ministry of Health, Labour and Welfare (MHLW) approved XEOMIN® for cervical dystonia and blepharospasm on June 19, 2026. An estimated 28,000 people in Japan suffer from blepharospasm, with tens of thousands more affected by cervical dystonia. Botulinum toxin injections are the first-line treatment, but only about half of patients report high satisfaction with existing options, and a significant minority discontinue due to unsatisfactory results or side effects. XEOMIN® offers a purified formulation that may provide a more durable or effective response for some patients.
Partnership execution and regulatory track record
The approval is the fifth indication won by the Teijin-Merz alliance since 2017, following approvals for upper limb spasticity (2020), lower limb spasticity (2021), and chronic sialorrhea (2025). The partnership combines Merz's global neurotoxin expertise and clinical data with Teijin's domestic market knowledge, sales infrastructure, and regulatory navigation skills. This step-by-step market penetration strategy builds trust with regulators and clinicians, demonstrating a de-risked pathway for foreign innovation in Japan's complex pharmaceutical ecosystem.
The 'pure toxin' clinical differentiator
XEOMIN®'s active ingredient, incobotulinumtoxinA, is produced via a proprietary process that removes complexing proteins, leaving only purified neurotoxin. For chronic conditions requiring repeated injections over years, this may reduce the risk of neutralizing antibody formation that can render treatment ineffective. The MHLW approval was supported by global Phase III trials and dedicated Phase III studies in Japanese patients, including a 48-week blepharospasm study confirming sustained efficacy and safety. This local validation is critical for Japanese regulators.
What buyers should watch
Japan's botulinum toxin segment is projected to exceed $700 million by 2034, with an estimated 11.3% CAGR. The market has long been dominated by Allergan (AbbVie) and Ipsen. The Teijin-Merz partnership's success offers a blueprint for challenging this duopoly, combining global science with local execution. For overseas distributors and clinic buyers, this development signals growing demand for purified neurotoxin formulations and associated consumables (e.g., injection devices, reconstitution supplies) in Japan. It also highlights the importance of local regulatory partnerships for market entry.
Sourcing context
Teijin Pharma is a Japanese healthcare and industrial conglomerate; Merz Therapeutics is a German specialist in neurotoxins. Their exclusive license and co-development agreement was signed in 2017. The partnership has now secured five MHLW approvals in six years, reflecting strong regulatory acumen and a de-risked commercial pathway. For suppliers of aesthetic devices, injectables, and clinic setup materials, this indicates a growing, competitive market segment in Japan that may require localized distribution partnerships.
Source: Read the original report | Published: June 19, 2026